5:07 PM
 | 
Jul 27, 2009
 |  BC Extra  |  Clinical News

BrainCells reports BCI-952 data

BrainCells Inc. (San Diego, Calif.) reported mixed results from a Phase II trial of BCI-952 to treat major depressive disorder (MDD). A modified intent-to-treat (ITT) analysis showed the combination of low-dose...

Read the full 142 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >